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Background Patients’ beliefs about medicine may either reflect the necessity for treatment or concerns regarding the treatment.
We explored the extent to which these beliefs have an effect on thiopurine metabolite levels and premature discontinuation in
patients with inflammatory bowel disease (IBD).
Patients and methods Patients enrolled in the ‘Thiopurine response Optimization by Pharmacogenetic testing in Inflammatory
Bowel Disease Clinics’ (TOPIC) trial were asked to complete the Beliefs about Medicine Questionnaire (BMQ) 4 weeks after
thiopurine initiation. The BMQ measures perceptions about treatment necessity and concerns. On the basis of the necessity and
concern scores, patients can be categorized as accepting, ambivalent, indifferent, or skeptical. The thiopurine discontinuation
rates for these belief subgroups were compared by Kaplan–Meier curves. Furthermore, clinical response and metabolite levels
were compared between the belief subgroups.
Results A total of 767 patients with IBD started thiopurine treatment, of whom 576 (75%) completed the BMQ. Patients could
be classified as accepting (34%), indifferent (17%), ambivalent (34%), or skeptical (15%). Compared with patients in the accepting
group (discontinuation rate 22%), patients with an indifferent (35%; P= 0.02), ambivalent (37%; P< 0.01), or skeptical belief
(54%; P<0.01) had higher thiopurine discontinuation rates. No differences were observed in the steady-state thiopurine
metabolite levels between the different belief subgroups.
Conclusion Patients with a low perceived treatment necessity or high concerns toward IBD treatment were more likely to
discontinue thiopurine treatment prematurely. Extra attention toward these patients might prevent premature discontinuation.
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Introduction
Thiopurines are seen as the cornerstone in the maintenance
treatment of inflammatory bowel disease (IBD). Although
thiopurines are effective in the treatment of ulcerative
colitis (UC) and Crohn’s disease (CD), up to 40% of
patients discontinue treatment within 1 year [1,2]. Several
factors may result in early treatment discontinuation, such
as occurrence of side effects or lack of effectiveness. Apart
from the actual occurrence of side effects or the lack of
effectiveness, patients’ beliefs about the necessity for the
treatment (e.g. the personal need for the prescribed drug)
and concerns regarding potential drawbacks of treatment
(e.g. side effects, long-term effects, or dependence) may
influence the motivation to start and continue medication
[3,4].
Patients with IBD have relatively high levels of neces-
sity, which suggests a high need for medical treatment
[3,5]. Nevertheless, nonadherence to medication is reported
in 30–60% of patients [3,6]. This results in an increased
flare risk and a lower quality of life [6]. Nonadherence to
thiopurines might seduce the attending physician to an
unjustified switch to expensive biologic drugs in an effort to
control disease, thereby placing an increased burden on
healthcare resources. In IBD, as in other diseases, non-
adherence is more frequently encountered in patients with
stronger concerns or lower perceived necessity of treatment
[7–10].
Evaluation of treatment adherence is a challenge. Objective
methods to assess treatment adherence such as drug tests in
blood or urine are cumbersome and not available for all
drugs; therefore, adherence is frequently assessed by indirect
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and subjective methods [11,12]. Unfortunately, significant
discrepancies exist between self-reported adherence and
objective assays [13]. In thiopurine treatment, assessment of
the thiopurine metabolites 6-methylmercaptopurine ribonu-
cleotides (6-MMPR) and 6-thioguanine nucleotide (6-TGN)
levels is becoming increasingly available in daily clinic for
optimization and evaluation of thiopurine treatment. The
presence of low levels of 6-MMPR and 6-TGN may suggest
noncompliance and can therefore be used as a tool to assess
treatment adherence [14]. Manipulation of adherence by
taking pills just before a hospital visit is less relevant with
thiopurines because it takes several weeks to achieve steady-
state metabolite levels.
Identification of patients at risk for nonadherence or early
treatment discontinuation would be useful in designing
a targeted approach to improve adherence. Apart from
the influence of personal beliefs on self-reported treatment
adherence and factors associated with adherence, little is
known on the effect of beliefs about medicine on steady-state
thiopurine metabolite levels and, more importantly, how
these beliefs may foresee treatment discontinuation [5,12].
To this end, we explored whether beliefs about IBD drugs
could be associated with metabolite levels or premature
treatment discontinuation of thiopurines.
Patients and methods
Patients
The current study is a post-hoc analysis of the Thiopurine
response Optimization by Pharmacogenetic testing in
Inflammatory bowel disease Clinics (TOPIC) trial. In the
TOPIC trial, thiopurine-naive patients with IBD were ran-
domized for standard-of-care thiopurine dosing versus a
genotype-based dose to evaluate the efficacy of pretreatment
thiopurine S-methyltransferase genotyping on the occur-
rence of myelosuppression [15]. Patients were followed for
20±6 weeks. Physicians were free to use either azathioprine
or mercaptopurine. The main exclusion criteria were pre-
vious use of thiopurines, laboratory test abnormalities,
known thiopurine S-methyltransferase enzyme activity, or
genotype. The study protocol of the TOPIC trial was
approved by the Institutional review board of the Radboud
University Medical Center. All patients provided written
informed consent. The TOPIC trial was registered at clin-
icaltrials.gov, NCT00521950. The TOPIC trial complies
with the Declaration of Helsinki. For a detailed description
of the study design, patient selection, and patient data, we
refer to Coenen et al. [15].
Beliefs about Medicine Questionnaire
Patients participating in the TOPIC trial were asked to
complete the Beliefs about Medicine Questionnaire (BMQ)
and the Medication Adherence Report Scale (MARS)
4 weeks after thiopurine initiation. Personal needs and
concerns regarding a treatment can be quantified with the
BMQ [16]. The BMQ is validated in patients with various
chronic diseases such as asthma, rheumatoid arthritis,
diabetic, renal dialysis, chronic heart disease, IBD, and
psychiatric diseases [16,17].
For this study, the BMQ included statements about IBD
treatment in a random order in terms of the necessity (five
questions; e.g. My future health depends on the use of my
IBD medication) and concerns (six questions; e.g. The use
of these IBD drugs disrupt my life). Statements are scored
on a Likert-type scale (ranging from 1= strongly disagree
to 5= strongly agree). The sum of answers for the five
statements about necessity leads to a score between 5 and
25. For concern statements, the sum of answers was divi-
ded by 6 (the number of statements) and multiplied by 5 to
generate a score between 5 and 25. Plotting the necessity
score at the y-axis and the concerns score at the x-axis,
with a split at the midpoint, enables a classification into
four belief subgroups (Table 1) [7].
Self-reported adherence
Self-reported adherence was assessed using the five-item
MARS questionnaire [16]. Questions are related to several
statements concerning adherence (e.g. I forget to take my
medication or I take fewer pills than prescribed). Answers
were provided on a five-point Likert scale. The sum of
answers was used as a subjective marker of adherence,
with a maximum score of 25, which can be considered full
(self-reported) adherence.
6-Methylmercaptopurine ribonucleotides and
6-thioguanine nucleotide metabolite measurements
By protocol, 6-TGN and 6-MMPR levels at week 8 were
assessed at a routine check-up in the first 301 patients
included in the TOPIC trial. 6-TGN and 6-MMPR levels
were determined in red blood cells (RBCs) by high-
performance liquid chromatography according to the
Lennard method [15]. Thiopurine metabolite concentra-
tions are presented in pmol/8×108 RBCs. For analyses
with metabolite levels, we used data from patients without
dose adjustments in the first 8 weeks. Subtherapeutic levels
were defined as 6-TGN levels below 230 pmol/8× 108
RBCs, whereas therapeutic levels were defined as 6-TGN
levels between 230 and 490 pmol/8×108 RBCs [18].
Clinical response
Clinical response was evaluated using the Harvey–Bradshaw
Index in patients with CD and the partial Mayo score in
patients with UC. Disease activity was measured at baseline,
week 0, and at the end of the clinical trial, week 20 [19].
Treatment response was defined as a reduction of three or
more points at week 20 compared with week 0 on either the
Harvey–Bradshaw Index or the partial Mayo score.
Data analysis
For this study, all patients who completed the BMQ were
included. One missing answer per subscale (necessity, concerns,
or self-reported adherence part) was accepted; in that case, the
Table 1. Classification of patients into four belief subgroups on the basis
of the Beliefs about Medicine Questionnaire score on the necessity and
concerns regarding inflammatory bowel disease treatment





A high score on both the necessity and the concern subscale is defined as a score
of more than 15 points and a low score is defined as 15 points or lower.
168 European Journal of Gastroenterology & Hepatology February 2018 •Volume 30 •Number 2
missing value was replaced by the mean of the other answers
on that subscale. Patients were excluded from this study
if more than one answer per subscale was missing. Scores
are presented as mean±SD, unless mentioned otherwise.
Differences between respondents and nonrespondents were
compared using a parametric and a nonparametric test, where
appropriate. Necessity and concerns scores were compared for
CD and UC using an independent-samples t-test. In the same
way, necessity and concerns scores were compared between
patients who continued and discontinued their thiopurine
during the 5 months after treatment initiation. Treatment dis-
continuation was defined as a patient who stopped the initial
prescribed thiopurine within 5 months. Dose reductions and
temporary interruptions were accepted, provided that the
interruption was not longer than 1 month [20]. Kaplan–Meier
curves were plotted to illustrate the time to discontinuation
for the four belief subgroups and the log-rank test was used to
compare discontinuation rates. Self-reported adherence rates
were compared between the different belief subgroups using
the Kruskal–Wallis test. The Kruskal–Wallis test was used to
compare 6-MMPR and 6-TGN levels between the different
belief subgroups and the χ2-test was used to compare the
number of patients with 6-TGN levels within the therapeutic
range. The degree of correlation between self-reported adher-
ence scores and metabolite levels was examined by Spearman’s
correlation coefficient. Differences in treatment response for
the belief subgroups were compared using the chi-squared
test. A P-value of less than 0.05 was considered significant.
All analyses were carried out in SPSS, version 22.0.0.1
(SPSS Inc., Chicago, Illinois, USA).
Results
Patients
Of the 796 randomized patients in the TOPIC trial, 767
patients actually started with thiopurines and 601 (78%)
returned the BMQ. A total of 25 returned questionnaires
were excluded because of more than one missing answer in
one of the three subscales, leaving 576 (75%) patients, the
respondents who successfully completed the questionnaires for
further analysis. Patients who did not return the questionnaire
(n=166) or who were excluded because of missing answers
(n=25) were classified as nonrespondents. The characteristics
of respondents and nonrespondents are shown in Table 2.
Beliefs about medicine
Patients with IBD scored (17.1 ± 4.2) on the necessity
subscale. Necessity scores were higher in patients with UC
(17.8 ±4.2) than CD (16.6 ± 4.1) (P< 0.01). Concern
scores were not different between UC (15.6±3.4) and CD
(15.1±3.4) (P=0.07). Categorization of patients according
to the combination of necessity and concerns score showed
that 34% of the patients could be defined as accepting, 34%
as ambivalent, 17% as indifferent, and 15% as skeptical
(Fig. 1).
Thiopurine discontinuation rates
Of the 576 respondents, 197 (34%) discontinued the initial
prescribed thiopurine within the first 5 months. Patients who
discontinued treatment had higher concerns (16.3±3.6 vs.
14.8±3.2, P<0.01) and lower necessity scores (16.1±4.9
vs. 17.7±3.6, P<0.01) than patients who continued thio-
purine treatment. Compared with patients in the accepting
group (discontinuation rate 22%), patients classified as
either indifferent (discontinuation rate 35%; P=0.02),
ambivalent (discontinuation rate 37%; P<0.01), or skep-
tical (discontinuation rate 54%; P<0.01) all had higher
discontinuation rates (Fig. 2). Moreover, discontinuation
rates of patients with a skeptical profile were also higher
compared with patients classified as either indifferent or
ambivalent (P<0.01).
Self-reported adherence
Self-reported adherence scores, measured with the MARS
questionnaire, were very high, with a median score (inter-
quartile range) of 25.0 (24.0–25.0). Self-reported adherence
scores were not different between the belief subgroups
(P=0.88). 6-MMPR metabolite levels (P=0.29) and 6-TGN
metabolite levels (P=0.34) were not correlated with the self-
reported adherence.
Thiopurine metabolite levels
Overall, 196 (65%) of the 301 patients in whom the week
eight 6-MMPR and 6-TGN levels were assessed were
considered as steady state (i.e. had no dose adjustments
during the first 8 weeks) and were included for further
analyses [21]. The number of patients per belief subgroup
with 6-TGN levels within the therapeutic range varied
between 43 and 48%. 6-MMPR (P= 0.99), 6-TGN
(P= 0.97) levels and the percentage of patients within the
therapeutic range (P= 0.97) were not different between the
four belief subgroups (Table 3).
Clinical response
Clinical response was known for 338 (58.7%) of the 576
respondents. Categorization of these 388 patients in belief
subgroups showed that 35% of the patients could be
classified as accepting, 35% as ambivalent, 16% as indif-
ferent, and 14% as skeptical, which is in line with the
numbers of the entire group (Fig. 1). Treatment response
rates per belief subgroup were 26% (30 out of 117) for
accepting patients, 26% (31 out of 121) in ambivalent
patients, 17% (nine out of 54) in indifferent patients, and
34% (16 of 47) in skeptical patients (Fig. 3). Treatment
response was not different between the four belief sub-
groups (P=0.26).
Discussion
The present study shows that patients with IBD who per-
ceive a low necessity or high concerns for IBD treatment
were more likely to discontinue thiopurine treatment pre-
maturely. Categorization into four belief subgroups
showed that most patients could be classified as accepting
or ambivalent. We found no association between belief
subgroups and 6-MMPR and 6-TGN metabolite levels.
The proportion of patients per belief subgroup corro-
borates with those found in previous studies in IBD
patients [3,22]. The relatively high scores of patients
toward the necessity for treatment probably follow from a
high level of disease burden in patients with IBD [23,24].
Application of the BMQ in diseases with a lower disease
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burden, such as atrial fibrillation, indeed results in lower
necessity scores than thrombosis, which has more impact
[25]. The higher necessity scores of UC patients compared
with patients with CD might be explained by the fact that
UC exacerbations with frequent bloody diarrhea may be
perceived as more severe compared with CD, which can be
more subtle in presentation [26]. The fact that a third of
the patients with IBD scored low on necessity for treatment
may have resulted from the cyclical disease manifestation
with episodes of no or only minimal disease symptoms
[12].
A novel aspect of this study is that we correlated BMQ
scores with treatment discontinuation rates. To date, stu-
dies using the BMQ in patients with IBD mainly focused
on the exploration of factors associated with drug adher-
ence [12,27]. Knowledge of who discontinues treatment is
of high relevance, given the limited alternative options in
the treatment of IBD. We showed that IBD patients with
high concerns or low needs are at risk for premature dis-
continuation of thiopurines in the first months of treat-
ment. Moreover, the combination of both even further
increases this risk. Our findings corroborate studies in
patients with IBD that showed a positive relation between
the patients’ necessity and medication adherence and a
negative relation in case of high concerns [12]. In the
current study, the BMQ was collected 4 weeks after thio-
purine initiation, which is in line with comparable study
designs [25,28]. Although studies showed that patients’
beliefs are considered stable over time, the occurrence of
side effects within the first weeks may have resulted in
increased concern feelings at the time that the ques-
tionnaire was completed [29]. Identification of patients at
risk for treatment discontinuation in an early stage might
help in the design of strategies to prevent them from dis-
continuing treatment. Special attention should be paid to
patients with high concerns as within the spectrum of IBD
drugs, patients consider thiopurines as drugs with the
highest risks as a result of fear of side effects and long-term
drug-induced comorbidities [30]. This leads to significantly
lower adherence rates for thiopurine use [31]. A compre-
hensive education at start and follow-up phone calls by an
IBD nurse or pharmacist seem to be a promising approach
to evaluate and anticipate the negative perceptions and
expectations toward thiopurine treatment [6,32–34].
This study is unique as thiopurine metabolite levels were
used as an indicator for treatment adherence in conjunction
with self-reported adherence scores. Most studies only used
self-reported adherence or pill count as a proxy for treatment
adherence [3,9]. In our study, patients scored very high on
self-reported adherence, whereas the number of patients in
the therapeutic range varied around 45%. Previous studies
reported lower self-reported adherence scores, suggesting
that self-reported adherence scores in this study might be
biased because of the setting of a clinical trial [3,7,9,24].
Only a few studies have compared self-reported adherence
with thiopurine metabolite levels measured in blood. In one
Table 2. Characteristics of respondents and nonrespondents
Total (n=767) [n (%)] Respondents (n=576) [n (%)] Nonrespondents (N=191) [n (%)] P-value
Age [median (IQR)] (years) 41 (27–53) 43 (28–55) 37 (24–47) <0.01
Sex: female 421 (55) 323 (56) 98 (51) 0.25
Disease type, CDa 463 (60) 336 (59) 127 (66) 0.05
Disease duration [mean (SD)] (years) 5.3 (8.2) 5.7 (8.6) 4.1 (6.9) 0.01
Baseline disease severityb
CD (HBI) [mean (SD)] 3.5 (3.0) 3.2 (2.7) 4.3 (3.8) 0.01
UC (partial Mayo score) [mean (SD)] 3.8 (1.7) 3.8 (1.7) 4.3 (1.7) 0.10
Type of thiopurine, AZA 494 (64) 380 (66) 114 (60) 0.12
Discontinuation before week 20 296 (39) 197 (34) 99 (52) <0.01
The nonrespondents group is composed of patients who did not return the questionnaire (n=166) and patients with more than 1 missing answer in one of the three
subscales (n=25).
AZA; azathioprine, CD; Crohn’s disease, HBI; Harvey–Bradshaw Index, IQR, interquartile range; UC; ulcerative colitis.
aSeven patients were diagnosed with indeterminate colitis.
bHBI was known for 349 patients with CD and the partial mayo score was known for 251 UC patients.
Fig. 1. Categorization of patients in four belief subgroups on the basis of
their necessity and concerns score, including the discontinuation rate per
belief subgroup.
Fig. 2. Kaplan–Meier curve in which treatment discontinuation is plotted for
the four belief subgroups: accepting group (n=198), ambivalent group
(n= 198), indifferent group (n= 96), and skeptical group (n=84).
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of these studies, self-reported nonadherence was limited to
10% of thiopurine users, whereas in practice, only 14% had
6-TGN levels within the therapeutic range [13]. It must be
stressed that many genetic and environmental factors influ-
ence thiopurine metabolism, which limits analyses between
necessity or concern scores and metabolite levels [35]. This
underscores the relevance, but also the difficulty, of more
objective outcome measures. We found no association
between the four belief subgroups and 6-MMPR and 6-TGN
metabolite levels at week 8. Furthermore, there were no
differences in treatment response between the belief sub-
groups, which seems logical, given the similar 6-MMPR and
6-TGN levels across the belief subgroups. This indicates that,
at least in the short term, the BMQ does not allow to predict
adherence or treatment response in patients with IBD, but
only who will discontinue treatment.
A limitation of our study is that obtaining metabolite
levels at week 8 might be too early in the follow-up to
identify differences in levels between the belief subgroups.
Nonadherence risk increases with length of treatment,
whereas in this study, patients just started treatment and
might still be motivated to take their pills [36]. This is sup-
ported by a study in 65 patients with IBD with an average
thiopurine usage of almost 3 years, in which metabolite
levels were significantly lower in patients with a low self-
reported adherence [37]. Furthermore, we only used data
from patients with steady-state week 8 metabolite levels.
Patients with dose adjustments, frequently because of side
effects, were excluded. Importantly, proportions of the four
belief subgroups of patients with steady-state metabolite
levels merely corresponded with numbers of the entire study
group, which makes selection bias unlikely. Another lim-
itation is that selection bias occurred, given the differences
between respondents and nonrespondents in age, disease
duration, and discontinuation rates. The latter can partially
be explained by patients who discontinued treatment before
week 4 and subsequently did not return the questionnaire
[38,39]. Finally, questions in the BMQ and MARS ques-
tionnaire contained the term ‘IBD treatment’ rather than
‘thiopurine treatment’ to avoid confusion with complicated
chemical drug names (azathioprine or mercaptopurine) or
brand names. Therefore, it might be that patients did not
answer the questions with reference to thiopurine use.
However, we foresee that this influence is minimal as
patients were asked to participate in a trial that focused on
the initiation of thiopurines.
Conclusion
The use of the BMQ helps to identify IBD patients who are
likely to discontinue thiopurines in the first months of
treatment. Attention and education in the consulting room
or by telephone should be given to patients with low needs
and high concerns toward IBD treatment to prevent pre-
mature discontinuation.
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